Bio-Tissue

BioTissue is a commercial-stage company focused on regenerative healing using processed human birth tissue allografts. It operates in two core segments: ocular (e.g., Prokera for corneal healing) and surgical (e.g., AmnioGraft for wound care), though it recently divested its non-ocular surgical business to sharpen its focus on ophthalmology. The company's competitive edge is rooted in its CryoTek cryopreservation and SteriTek shelf-stable processing technologies, which aim to preserve key biological components lost in conventional processing. With over 40 years of collective R&D, 1M+ clinical applications, and a strong publication record, BioTissue is an established player in the biologics and tissue engineering space.

Proprietary tissue preservation platforms: CryoTek (cryopreservation to retain native tissue biology) and SteriTek (room-temperature, hydrated preservation without heat dehydration).

BioTissue competes with numerous other companies offering amniotic membrane and umbilical cord allografts, such as MiMedx Group, Organogenesis, StimLabs, and Skye Biologics. Its differentiation is based on its proprietary CryoTek and SteriTek processing methods, which it claims preserve more native biological activity than standard dehydrated allografts.